|
Originally published In Press as doi:10.1074/jbc.M112054200 on April 26, 2002
J. Biol. Chem., Vol. 277, Issue 28, 24889-24895, July 12, 2002
Contribution of Macrophage Migration Inhibitory Factor to
Extracellular Signal-regulated Kinase Activation by Oxidative Stress in
Cardiomyocytes*
Jun
Fukuzawa §,
Jun
Nishihira¶,
Naoyuki
Hasebe ,
Takashi
Haneda ,
Junzo
Osaki ,
Tetsuya
Saito ,
Tomoaki
Nomura ,
Takayuki
Fujino**,
Nobutaka
Wakamiya , and
Kenjiro
Kikuchi
From the First Department of Medicine,
** Department of Pharmacology, and
 Department of Microbiology, Asahikawa Medical College,
2-1-1-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan, the
¶ Central Research Institute, Hokkaido University School of
Medicine, Kita 15 Nishi 7 Kita-ku Sapporo 060-8638, Japan, and the
Nemuro Municipal Hospital, 1-2 Ariiso, Nemuro 087-8686, Japan
Received for publication, December 18, 2001, and in revised form, March 26, 2002
 |
ABSTRACT |
In response to oxidative stress, the pathogenesis
of a number of cardiovascular events and several genes are stimulated
by extracellular signal-regulated kinases (ERK1/2). Biphasic (early, 10 min; and delayed, 120 min) ERK1/2 activation by
H2O2, a reactive oxygen species, was
observed in cultured neonatal rat cardiomyocytes. We investigated the
hypothesis that the delayed activation of ERK1/2 depends on a factor
secreted by oxidative stress (FSO). The delayed activation was
inhibited by calphostin C, a protein kinase C inhibitor.
Conditioned medium (CM) obtained from cells stimulated with
H2O2 induced rapid and monophasic ERK1/2
activation, which was not inhibited by calphostin C. In contrast,
calphostin C-pretreated CM did not activate ERK1/2. Macrophage
migration inhibitory factor (MIF) was one of the candidate FSOs
activating ERK1/2. The existence of MIF in CM, the recombinant
MIF-stimulated ERK1/2 rapid activation, and anti-MIF neutralizing
antibody-induced inhibition of the delayed activation implied that MIF
could be the FSO. Pretreatment of cardiomyocytes with a
mitogen-activated protein kinase/ERK kinase (MEK) inhibitor did not
suppress the MIF secretion, although it prevented the ERK1/2 activation
by H2O2. These results indicate that MIF is
secreted from cardiomyocytes as a result of oxidative stress and
activates ERK1/2 through a MEK1/2-dependent mechanism,
although the secretion is not regulated by ERK1/2 but by protein
kinase C.
 |
INTRODUCTION |
Oxidative stress is important in the pathogenesis of
ischemic/reperfusion injury (1, 2), apoptosis (3, 4), and hypertrophy
in cardiomyocytes (5, 6). In response to reactive oxygen species
(ROS),1 transcription of
several genes is activated through some mechanisms in which association
with stimulated protein kinases is included (7). Mitogen-activated
protein kinases (MAPKs), which are serine/threonine protein kinases,
regulate gene promoter activity and play an important role in
anti-apoptosis and cell growth (8, 9). The targets for extracellular
signal-regulated kinase (ERK1/2), a classical molecule in the MAPK
family (10), are nuclear transcription factors, metabolic enzymes,
cytoskeletal proteins, and other signaling components (11). ERK1/2 acts
as a modulator of many aspects of cellular function and is acutely
stimulated by growth and differentiation factors, including oxidative
stress in pathways mediated by receptor tyrosine kinase, G
protein-coupled receptors, or cytokine receptors (11). However, the
number and nature of the mechanisms leading to activation of ERK1/2
evoked by oxidative stress, that is, redox-sensitive regulation in
cardiomyocytes, are poorly understood at present. Some reports
have shown that ERK1/2 is activated biphasically not only by basic
fibroblast growth factor and nerve growth factor but also by hydrogen
peroxide (H2O2) and ROS generators such as LY83583 in vascular smooth muscle cells (12-14). The mechanism of late
phase activation of ERK1/2 by oxidative stress has not been well
examined, although early phase activation of ERK1/2 by oxidative stress
has been well studied (15). One of the possible mechanisms of the
late-phase activation of ERK1/2 by H2O2 is
autocrine and paracrine secretion of the factors activating ERK1/2
(14).
Macrophage migration inhibitory factor (MIF), initially identified as a
soluble factor derived from activated T lymphocytes, is a cytokine that
plays a critical role in several inflammatory conditions by
regulating the activation of macrophages and T cells (16-19), although
its precise biological function remains unclear (20). However, after
cloning of the MIF cDNA, previously unrecognized endocrine and
enzymatic functions of MIF were revealed. It also acts as a
proinflammatory cytokine produced by macrophages in response to a
variety of inflammatory stimuli and as a factor stimulating cell growth
in many cell types (18, 21). The responses of cardiovascular systems to
MIF have not been reported except for mRNA and protein expression
of MIF in the atherosclerotic region in a hypercholesterolemic
model of rabbit vessels (22). Recently, increased serum concentrations
of MIF have been reported in patients with acute myocardial infarction
in which reperfusion injury may be involved (23).
We hypothesized that cardiomyocytes could secrete factors increasing
ERK1/2 activity in response to ROS and that MIF could be an important
secreted ROS-induced factor in cardiomyocytes. To explore this
hypothesis, we used cultured cardiomyocytes from neonatal rat to
examine whether H2O2 induced MIF secretion in cardiomyocytes and to investigate the mechanism and the relationship between MIF and H2O2-induced ERK1/2 activation.
 |
MATERIALS AND METHODS |
Reagents and Antibodies--
Reagents for tissue culture were
obtained from Invitrogen. Polyclonal antibodies against
phosphospecific and total ERK1/2 and phosphospecific and total MEK1 or
1/2 were from Santa Cruz Biotechnology (Santa Cruz, CA). PD98059,
geldanamycin, and calphostin C were purchased from Calbiochem. Rat
recombinant MIF was expressed in Escherichia coli and
purified to homogeneity as described previously (24). A polyclonal
anti-rat MIF antibody was generated by immunizing New Zealand White
rabbits with recombinant rat MIF as reported previously (25).
Isolation and Culture of Neonatal Rat Ventricular
Cardiomyocytes--
Cardiomyocytes were isolated from 1-2-day-old
Sprague-Dawley rat ventricles by an enzymatic method as described
previously (26-28). Twenty-four hours after isolation,
serum-containing medium was changed to Dulbecco's modified Eagle's
medium/F-12 with a serum substitute as described previously (29).
Twenty-four hours before experiments, cells were given the same medium
without the serum substitute. Using these methods, cultures that
contained 90-95% myocytes were obtained (26).
Immunoblot Analysis--
Cardiomyocytes were lysed after each
stimulation with a buffer as described previously (30). The lysed
samples were subjected to Tris-glycine-SDS-PAGE (8-10%). After
separation by electrophoresis, samples were transferred to
nitrocellulose membranes (Amersham Biosciences) and subjected to
immunoblot analysis using each indicated antibody (30). Signals were
visualized with enhanced chemiluminescence (PerkinElmer Life Sciences).
For detection of MIF, the samples were subjected to Tris-Tricine
SDS-PAGE as described previously (31). In each experiment, three
independent analyses were performed to confirm the reproducibility.
Preparation of Conditioned Medium--
Conditioned medium was
collected and concentrated according to a method described
elsewhere (14). Briefly, cells were washed three times with Hanks'
balanced salt solution (NaCl 130 mM, KCl 5 mM,
CaCl2 1.5 mM, MgCl2 1 mM, HEPES 20 mM, pH 7.4) and were equilibrated
for 24 h. H2O2 (1 mM)
was added to the Hanks' balanced salt solution pretreated with/or
without calphostin C (1 µM) or PD98059 (50 µM) or control medium from the cells unstimulated with
H2O2, were collected and centrifuged to remove
the debris at 800 × g at 4 °C for 10 min. The
conditioned medium pretreated with or without calphostin C or
PD98059 and the control medium were concentrated 100-fold by using a
CentriprepTM centrifugal filter device (Millipore, Bedford, MA).
Measurement of Hydrogen Peroxide Concentration--
The
concentration (degradation) of the exogenously added
H2O2 in the medium with or without cells was
measured with a Bioxytech H2O2-560TM (Oxis International
Inc., Portland, OR) according to the manufacturer's protocol.
 |
RESULTS |
H2O2-induced ERK1/2
Activation--
Exposure of cardiomyocytes to
H2O2 (1 mM) stimulated ERK1/2
phosphorylation (activation) with a peak at 10 min. The ERK1/2 activity
returned to the base-line level at 45-60 min. After returning to the
base line, a second peak of ERK1/2 activation appeared at 120 min (Fig.
1A). The concentration of
H2O2 that was added exogenously to the medium
decreased exponentially and returned to the basal (zero) level within
90 min after the exogenous administration (Fig. 1B).
Concentration dependences of H2O2 in the early
and late phases of ERK1/2 activation occurred in different manners (Fig. 1C). To evaluate whether
H2O2-induced ERK1/2 activation was mediated via
an ROS-dependent or -independent mechanism, cells were
treated with the antioxidant reagent, catalase (3000 units/ml) before
exposure to H2O2 (1 mM). Catalase
inhibited both the early and late phases of ERK1/2 activation in
response to H2O2 (Fig. 1D).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Hydrogen peroxide-induced ERK1/2
activation in cardiomyocytes. A, cultured
cardiomyocytes from neonatal rats were stimulated with 1 mM
hydrogen peroxide (H2O2) for the indicated
times. For an examination of the ERK1/2 activity, cells were harvested
using lysis buffer, separated by SDS-PAGE, transferred to
nitrocellulose membranes, and subjected to immunoblot analysis using
anti-phosphospecific ERK1/2 (upper panel) and anti-ERK1/2
(lower panel) antibodies as described under "Materials and
Methods." Similar results were obtained from three independent
experiments. B, concentration of
H2O2 in the medium after the addition of
exogenous H2O2 (1 mM) was measured
as described under "Materials and Methods." The solid
and dotted lines indicate the H2O2
concentrations in the medium with cells and the cell-free medium,
respectively. C, cardiomyocytes were stimulated for 10 or
120 min with the indicated concentrations of
H2O2, and ERK1/2 activity was measured.
D, cardiomyocytes were pretreated with 3000 units/ml
catalase, an antioxidant, before H2O2 (1 mM) stimulation, and ERK1/2 activity was measured.
|
|
Roles of MEK, Raf-1, and PKC in
H2O2-induced ERK Activation--
To assess the
upstream mechanism of H2O2-induced ERK1/2
activation, cardiomyocytes were pretreated with reagents that inhibit MAPK/ERK kinase (MEK), Raf-1, or protein kinase C (PKC) before exposure
to H2O2. The addition of PD98059 (50 µM), an inhibitor of MEK, decreased both the early and
late phases of ERK1/2 activation in response to
H2O2 (Fig.
2A). The activity of MEK1/2
was also up-regulated biphasically by H2O2
administration into cultured medium as was that of ERK1/2 (Fig.
2B). Geldanamycin (2 µM), which can bind to
HSP-90 and disrupts the Raf-1-HSP90 multimolecular complex leading to
destabilization of Raf-1 (32), also inhibited both peaks (Fig.
2C). However, calphostin C (1 µM), a specific inhibitor of protein kinase C, diminished only the delayed activation of ERK1/2 by H2O2 (Fig. 2D).

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 2.
Involvement of MEK, Raf-1, and PKC in
H2O2-induced ERK1/2 activation.
A, cultured cardiomyocytes from neonatal rats were
preincubated for 30 min in the presence of PD98059 (50 µM) for the indicated times, separated by SDS-PAGE,
transferred to nitrocellulose membranes, and subjected to
immunoblot analysis using anti-phosphospecific ERK1/2 (upper
panel) and anti-ERK1/2 (lower panel) antibodies.
B, neonatal rat cultured cardiomyocytes were exposed to
H2O2 (1 mM) for the indicated
times. Samples were subjected to immunoblot analysis with
anti-phosphospecific MEK (upper panel) and
anti-MEK (lower panel) antibodies. C,
cardiomyocytes were preincubated with geldanamycin (2 µM) for 30 min followed by stimulation with
H2O2 (1 mM). D,
cardiomyocytes were preincubated with calphostin C (1 µM) for 30 min followed by stimulation with
H2O2 (1 mM). ERK1/2 activity was
measured as described under "Materials and Methods."
DMSO, dimethyl sulfoxide; NC, negative control
(unstimulated cells); PC, positive control (cells stimulated
with 1 mM H2O2 for 10 min).
|
|
Effect of Conditioned Medium Prepared by Exposing Cardiomyocytes to
H2O2 on ERK Activation--
Conditioned medium
obtained from the cells exposed to 1 mM
H2O2 (CM+) stimulated ERK1/2
activation rapidly and monophasically (Fig. 3A), whereas
H2O2-unstimulated control medium
(CM ) did not stimulate ERK1/2 activation (Fig.
3B). The conditioned medium was fractionated on a molecular
weight basis using a commercially available filter device. Adding each
fraction to the medium stimulated ERK1/2 activation in cardiomyocytes.
CM10-30, CM50, and CM30-50, to a lesser extent, could stimulate
ERK1/2 activation (Fig. 3C). In contrast to the
H2O2-stimulated cells, catalase did not inhibit ERK1/2 activation in cells stimulated with CM+ (Fig.
3D). Calphostin C-pretreated conditioned medium obtained from the cells stimulated with H2O2 (1 mM) showed suppressed ERK1/2 activation (Fig.
4A). In contrast, the
conditioned medium-stimulated rapid and monophasic activation of ERK1/2
was not inhibited by pretreatment with calphostin C (1 µM) (Fig. 4B).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of conditioned medium prepared by
exposing cardiomyocytes to H2O2 on ERK1/2
activation. Conditioned media obtained from the cardiomyocytes
stimulated with and without H2O2 (1 mM) for 120 min were concentrated using a centrifugal
filter system as described under "Materials and Methods."
Cardiomyocytes were stimulated with conditioned medium stimulated with
(A) or without (B) H2O2
for the indicated times. After stimulation with conditioned medium,
cells were subjected to SDS-PAGE, transferred to nitrocellulose
membranes, and subjected to immunoblot analysis using
anti-phosphospecific ERK1/2 (upper panel) or anti-ERK1/2
(lower panel) antibodies. C, collected
conditioned medium derived from cardiomyocytes stimulated with
H2O2 (1 mM) for 120 min was
fractionated using a centrifugal filtration system as described under
"Materials and Methods." Fractionation was performed according to
the molecular mass: CM3, less than 3 kDa;
CM3-10, 3-10 kDa; CM10-30, 10-30 kDa;
CM30-50, 30-50 kDa; CM50, more than 50 kDa).
Fractionated conditioned medium was applied to the
cardiomyocytes for 10 min, and the cells were subjected to
immunoblot analysis using anti-phosphospecific ERK1/2 and anti-ERK
antibodies. D, cardiomyocytes were preincubated with
catalase (3000 units/ml) for 30 min followed by stimulation with
H2O2 (1 mM) for the indicated
times. ERK1/2 activity was measured as described under "Materials and
Methods."
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
Secretion of
H2O2-induced factor by a calphostin
C-dependent mechanism and regulation of the secreted
factor-induced ERK1/2 activation by a calphostin C-independent
mechanism. A, medium derived from the cultured
cardiomyocytes preincubated with calphostin C (1 µM) for
30 min followed by H2O2 (1 mM) for
120 min was collected and concentrated (CMcalphostin) as
described under "Materials and Methods." The concentrated medium
was applied to the cells for the indicated times. The cells were
subjected to immunoblot analysis using anti-phosphospecific ERK1/2
(upper panel) and anti-ERK (lower panel)
antibodies. B, 30 min after calphostin C incubation,
neonatal cultured cardiomyocytes were exposed to the conditioned medium
derived from cells stimulated with H2O2 (1 mM) for 120 min (CM+), and the
ERK1/2 activation was assessed.
|
|
H2O2-induced MIF Secretion--
The MIF in
the conditioned medium was detected by Tris-Tricine SDS-PAGE and
immunoblotting, whereas no MIF was detectable in the control medium or
mock-stimulated medium (Fig.
5A). To confirm the effect of
ERK1/2 on MIF secretion induced by H2O2, PD98059 (50 µM)-pretreated conditioned medium was
analyzed. PD98059 did not inhibit
H2O2-induced MIF secretion from cardiomyocytes. However, protein kinase C inhibition by calphostin C (1 µM) inhibited H2O2-induced MIF
secretion. MIF concentration in the conditioned medium increased from
90 min after H2O2 stimulation (Fig.
5B). By contrast, MIF was not secreted in the calphostin
C-pretreated conditioned medium. To determine whether the
H2O2-induced MIF secretion was controlled via a
regulatory or constitutive mechanism (33), the changes in the MIF
concentration in cells stimulated with H2O2 (1 mM) were determined by using whole cell lysate.
Intracellular MIF contents were decreased at 90 and 120 min after
stimulation (Fig. 5C).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
MIF secretion from neonatal cultured
cardiomyocytes in response to H2O2
stimulation. A, conditioned medium obtained from cells
stimulated with H2O2 (1 mM) for 120 min was collected and concentrated 100× using a centrifugal filter
system as described under "Materials and Methods." Recombinant MIF
(rMIF) (1.4 µg, 140 ng, and 14 ng), the medium from the
cell-free dish (mock), the medium from the cells
unstimulated with H2O2, and conditioned medium
from the cells stimulated with H2O2 (1 mM) for 120 min were subjected to SDS-PAGE (15%), and
immunoblot analysis was performed using an anti-MIF antibody. The
medium obtained from the cells pretreated with PD98059 (50 µM) or calphostin C (1 µM) for 30 min
followed by H2O2 stimulation for 120 min was
also subjected to SDS-PAGE, transferred to nitrocellulose membranes,
and immunoblotted with the anti-MIF antibody as described under
"Materials and Methods." B, conditioned media derived
from the cardiomyocytes stimulated with H2O2
for the indicated times were collected and concentrated using the
centrifugal filter system. Conditioned media pretreated with calphostin
C (1 µM) followed by stimulation with
H2O2 for the indicated times were also
collected and concentrated. Each conditioned medium was subjected to
SDS-PAGE (15%), and immunoblot analysis was performed using an
anti-MIF antibody as described under "Materials and Methods."
C, cardiomyocytes were stimulated with
H2O2 (1 mM) for the indicated
times, separated by SDS-PAGE, transferred to nitrocellulose membranes,
and subjected to immunoblot analysis using the anti-MIF antibody as
described under "Materials and Methods."
|
|
Effect of MIF and Anti-MIF Antibody on ERK1/2
Activation--
Cells stimulated with a high concentration of
recombinant MIF showed rapid and monophasic activation of ERK1/2-like
conditioned medium-stimulated cells (Fig.
6A). We also determined the
effect of an anti-MIF antibody on H2O2-induced
ERK activation. Anti-MIF antibody (1:1000) pretreatment inhibited the
late phase activation of ERK1/2, whereas pretreatment of the cells with
preimmune serum did not decrease the
H2O2-induced late phase activation (Fig. 6B). In each ERK1/2 activation stimulated with the
conditioned medium fractionated by the centrifugal filtration system,
CM30-50-induced ERK1/2 activation was completely inhibited by
the anti-MIF antibody, and the one stimulated with CM10-30 was
partially inhibited (Fig. 3C).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of MIF and anti-MIF antibody on
ERK1/2 activation in neonatal rat cultured cardiomyocytes.
A, cells were exposed to recombinant MIF (rMIF)
(1 µg/ml) for the indicated times and harvested. ERK1/2 activity was
assessed by immunoblot analysis. B, cells were pretreated
with or without nonimmune serum or the anti-MIF antibody followed by
H2O2 (1 mM) stimulation for the
indicated times. The activity of ERK1/2 was examined as described under
"Materials and Methods." C, cells were pretreated with
the anti-MIF antibody (1 µg/ml) followed by stimulation with
fractionated conditioned media and were subjected to
immunoblot analysis using anti-phosphospecific ERK1/2 and
anti-ERK1/2 antibodies.
|
|
 |
DISCUSSION |
The MAPK signaling pathway plays a pivotal role in the mediation
of cellular responses to a variety of signaling molecules. ERK1/2
regulates cell growth, embryonic development, cell survival (9), and
cell differentiation in different cell types through the
stimulation of specific gene expression. The signaling pathway for
ERK1/2 activation includes intracellular calcium, heterotrimeric G
proteins, protein kinase C, JAK/STAT (Janus kinase/signal transducers and activators of transcription) pathways, and phosphatidylinositol 3-kinase. in cardiomyocytes the Src/Ras/Raf-1 cascade has also been
reported as a pathway for the redox-sensitive regulation of ERK1/2 in
the early phase (15). In the present study, we observed that
exogenously supplied H2O2 (1 mM)
caused biphasic activation of ERK1/2, which was inhibited by catalase,
an antioxidant reagent, in cultured cardiomyocytes from neonatal rats.
The mechanism of this phenomenon was inferred to be
ROS-dependent. Pharmacological blockade of the Raf-1/MEK
cascade activation suppressed the activation in both phases. On the
other hand, inhibition of the PKC pathway by calphostin C blocked only
the late-phase activation of ERK1/2 in response to
H2O2.
It was obvious that stimulation by regeneration of
H2O2 could be excluded as a mechanism for the
late phase activation of ERK1/2 by H2O2. The
concentration of the exogenously applied H2O2 in the medium decreased exponentially in the presence of the cells (Fig. 1B). The phenomenon of biphasic ERK1/2 activation in
various cells has already been reported. Like
H2O2, basic fibroblast growth factor, nerve
growth factor, and ROS generators such as LY83583 were reported to
stimulate the biphasic ERK1/2 activation (12-14). The Ras/Raf/MEK
cascade is known as an ERK1/2 activation system. In the present study,
Raf-1 and MEK were shown to be upper signaling cascades for both phases
of the ERK1/2 activation. Because geldanamycin, which was used as an
inhibitor of Raf-1 in the present experiments, could function as an
inhibitor of HSP-90 (32), biphasic activation of ERK1/2 with
H2O2 could also be explained by an
HSP-90-related mechanism. Further examination will be needed to confirm
whether the phenomenon is HSP-90-dependent. We have demonstrated
that the late phase activation of ERK1/2 is PKC-dependent.
Although PKC is also known as a Raf-1 stimulator followed by ERK1/2
activation, the early phase activation of ERK1/2 by
H2O2 was not mediated through this cascade in
the present experiments. This indicated that the mechanisms of
H2O2-induced ERK1/2 activation were different in the early and late phases. This finding was supported by the differences in H2O2 concentration dependence of
ERK1/2 activation between the early and late phases.
PKC plays important roles in many cellular responses in various types
of cells. These responses include contraction, migration, hypertrophy,
proliferation, apoptosis, and secretion (34). In addition, lung
surfactant phospholipid from alveolar type II cells is secreted via a
conventional type PKC (PKC- and - )-dependent mechanism (35). Considering these reports, we hypothesized that the
mechanism of the PKC-dependent late phase activation of
ERK1/2 by H2O2 could be explained by a factor
secreted by oxidative stress (FSO). To examine this hypothesis, we
examined the effect of conditioned medium derived from the cells
stimulated with H2O2 (1 mM) for 120 min on ERK1/2 activation in cardiomyocytes. As demonstrated in Fig. 3,
concentrated control medium obtained from the cells unstimulated with
H2O2 did not activate ERK1/2 in cardiomyocytes. In contrast, the concentrated conditioned medium rapidly and
monophasically activated the ERK1/2. These facts confirmed the
hypothesis that a secreted factor plays a key role in the
H2O2-induced late phase activation of ERK1/2 in
cardiomyocytes. Catalase, which abrogated H2O2-induced ERK activation, did not inhibit
the rapid and monophasic activation of ERK1/2 induced by conditioned
medium. This suggested that the mechanism of the conditioned
medium-induced ERK1/2 activation was independent of ROS. The decay of
H2O2 shown in Fig. 1 indicated that the
mechanism of the residual H2O2 in the medium
was excluded for the rapid and monophasic activation of ERK1/2 by
conditioned medium. Conditioned medium pretreated with calphostin C did
not activate ERK1/2 in cardiomyocytes, as demonstrated in Fig. 4. This,
along with the result that the late phase activation of ERK1/2 by
H2O2 was PKC-dependent, indicated
that the mechanism of the oxidative stress-induced secretion was
PKC-dependent.
In the present study, we demonstrated that the ERK1/2 activation in
conditioned medium could be fractionated into various molecular weight
ranges and that each fraction induced ERK1/2 activation to some extent.
This indicated that some secreted factors were responsible for the late
phase activation. By means of a literature search (36), we examined
which growth factors or cytokines were activated by oxidative stress,
including ischemia and hypoxia, and stimulated ERK1/2 activation.
Considering the molecular weight, MIF could be one of the
candidate molecules that activate ERK1/2. The molecular weight of MIF
is 13,000; it forms oligomers, especially trimers, as confirmed
by crystal structure analysis (37-39) and cross-linking studies (40,
41). It has been reported to stimulate ERK1/2 in fibroblasts via a
protein kinase A-dependent pathway (42). MIF was originally
described as a T-cell-derived cytokine that inhibits macrophage
migration in vitro and promotes macrophage accumulation in
the delayed-type hypersensitivity reaction (16, 17). As shown in Fig.
6, we observed that neutralizing antibodies against MIF partially
inhibited the late phase activation of ERK1/2 by
H2O2 and that recombinant MIF induced ERK1/2
activation in a manner similar to the ERK1/2 activation induced by
conditioned medium. The medium fraction of CM30-50 (containing major
parts of the MIF trimer)-induced ERK1/2 activation was completely
inhibited and that of CM10-30 (containing a possible MIF monomer or
dimer) was partially inhibited by the anti-MIF antibody. These results
suggested that MIF can act as a monomer or oligomer and that some other
factors, induced by H2O2 and increased ERK1/2
activation, existed in the CM10-30. These results indicated that MIF,
either alone or with one or more other factors, could be the FSO.
Factors secreted in response to oxidative stress mediate production of
the oxidative stress-induced growth factor in several cell types (43).
Although different growth factors are involved depending on the type of
tissue as well as the type of oxidative stress, it is obvious that
responses in an autocrine/paracrine manner could be a common mechanism
utilized in oxidative stress-induced signal transduction. MIF mRNA
expression in cardiomyocytes was up-regulated 6 h after
H2O2 stimulation (44), and the concentration of
MIF in the cardiomyocytes decreased after H2O2
stimulation. It is likely that myocytes utilize the regulated type
(preformed MIF within cells) but not the constitutive type of secretion
for oxidative stress-induced MIF secretion, like atrial natriuretic factor secretion in response to endothelin (45). This suggests that
oxidative stress causes secretion of preformed MIF, although an
oxidative stress-induced increase in MIF production is likely to
occur at a later stage. Several possibilities could be
considered for the mechanism of MIF secretion induced by oxidative
stress. First, oxidative stress activates signaling pathways such as
that of PKC, Ca2+, and small G protein (Rab), which may in
turn stimulate growth factor secretion. The present work suggests this
PKC-dependent explanation. Second, oxidative stress causes
an alteration in myocyte sarcolemmal permeability, which indicates
release of intracellular growth factors. Pacing-induced basic
fibroblast growth factor release from adult rat ventricular
cardiomyocytes accounts for this mechanism (46). Although the plasma
MIF level increases in patients with acute myocardial infarction, it
does not increase in patients with other ischemic conditions such as
unstable angina pectoris (23). These data suggest that MIF is secreted
from necrotic cardiomyocytes. Thus, these possibilities will have to be examined.
Next, the question arises as to whether linkage between the early phase
and late phase activation of ERK1/2 exists. PKC is known to stimulate
Raf-1 followed by ERK1/2 in some types of cells (47), indicating that
PKC signaling could be the upper signaling cascade for each phase of
ERK1/2 activation. As shown in Fig. 4, a PKC inhibitor, calphostin C,
inhibited neither conditioned medium-induced (that is, FSO-induced)
ERK1/2 activation nor H2O2-induced early phase
activation of ERK1/2, indicating that PKC was not the upper signaling
cascade for either early or late phase ERK activation evoked by
H2O2. A similar result for the early phase activation of ERK1/2 was reported previously (15). Because we used
calphostin C, known as a pan-specific PKC inhibitor, in the present
study as well as in a previous one (15), additional experiments using
isotype-selective PKC inhibitor such as Go-6983 will be needed to
determine which PKC isozymes contribute to the H2O2-induced MIF secretion. PD98059, an
inhibitor of MEK, and geldanamycin, an inhibitor of Raf-1, had
inhibitory effects on H2O2-induced ERK1/2
activation in both phases as demonstrated in Fig. 2, indicating that
the Raf-1/MEK pathway was the upper signaling cascade for ERK1/2
activation in both phases. On the other hand, ERK1/2 did not play a
major role in MIF secretion, which had been suggested by the finding
that H2O2-stimulated conditioned medium
pretreated with PD98059 did not affect the secretion of MIF from
cardiomyocytes, as shown in Fig. 5. These data indicate that the early
phase activation of ERK1/2 by oxidative stress is not required for the
late phase activation of ERK1/2. For the secretion of MIF, PKC plays a
key role. The present study indicated a novel role for MIF in the
mediation of the oxidative stress-induced signaling cascade
up-regulation in cardiomyocytes.
In summary, we have demonstrated that oxidative stress activates ERK1/2
biphasically in cardiomyocytes. A PKC-dependent mechanism contributes to the late phase activation of ERK1/2 by oxidative stress.
Secretion of MIF from cardiomyocytes themselves, induced by oxidative
stress, plays a key role in late phase activation of ERK1/2 through a
MEK-dependent mechanism, although its secretion is
not regulated by the MEK-ERK1/2 signaling cascade but by PKC. These
phenomena provide important insights into the cellular response to
oxidative stress.
 |
ACKNOWLEDGEMENTS |
We thank M. Yashima for excellent technical
assistance and the members of the First Department of Medicine,
Asahikawa Medical College, for helpful discussions.
 |
FOOTNOTES |
*
This work was supported in part by a grant for research on
cardiovascular disease from the Japan Heart Foundation/Pfizer
Pharmaceuticals Inc. and by Grant-in-aid (C)14570629 for Scientific
Research from the Ministry of Science, Sports, and Culture of Japan (to
J. F.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 81-166-68-2442;
Fax: 81-166-68-2449; E-mail: fukuzawa@asahikawa-med.ac.jp.
Published, JBC Papers in Press, April 26, 2002, DOI 10.1074/jbc.M112054200
 |
ABBREVIATIONS |
The abbreviations used are:
ROS, reactive oxygen
species;
MAPK, mitogen-activated protein kinase;
ERK, extracellular
signal-regulated kinase;
MEK, MAPK/ERK kinase;
FSO, factor secreted by
oxidative stress;
CM, conditioned medium;
MIF, macrophage migration
inhibitory factor;
PKC, protein kinase C;
Tricine, N-[2-hydroxy-1,1-bis- (hydroxymethyl)ethyl]glycine.
 |
REFERENCES |
| 1.
|
Turners, J. A.,
and Bovanis, A.
(1980)
Biochem. J.
156,
434-444
|
| 2.
|
Xia, Y.,
Katchikian, G.,
and Zweier, J. L.
(1996)
J. Biol. Chem.
271,
10096-10102[Abstract/Free Full Text]
|
| 3.
|
Gottlieb, R. A.,
Burleson, K. O.,
Kloner, R. A.,
Bobior, B. M.,
and Engler, R. L.
(1994)
J. Clin. Invest.
94,
1621-1628[Medline]
[Order article via Infotrieve]
|
| 4.
|
Tanaka, M.,
Ito, H,
Adachi, S.,
Akimoto, H.,
Nishikawa, T.,
Kasajima, T.,
Marumo, F.,
and Hiroe, M.
(1994)
Circ. Res.
75,
426-433[Abstract/Free Full Text]
|
| 5.
|
Nakamura, K.,
Fushimi, K.,
Kouchi, H.,
Mihara, K.,
Miyazaki, M.,
Ohe, T.,
and Namba, M.
(1998)
Circulation
98,
794-799[Abstract/Free Full Text]
|
| 6.
|
Tanaka, K.,
Honda, M.,
and Takabatake, T.
(2001)
J. Am. Coll. Cardiol.
37,
676-685[Abstract/Free Full Text]
|
| 7.
|
Nishida, M.,
Maruyama, Y.,
Tanaka, R.,
Kontani, K.,
Nagao, T.,
and Kurose, H.
(2000)
Nature
408,
492-495[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Thorburn, J.,
Frost, J. A.,
and Thorburn, A.
(1994)
J. Cell Biol.
126,
1565-1572[Abstract/Free Full Text]
|
| 9.
|
Xia, Z.,
Dickens, M.,
Raingeaud, J.,
Davis, R. J.,
and Greenberg, M. E.
(1995)
Science
270,
1326-1331[Abstract/Free Full Text]
|
| 10.
|
Erikson, E.,
and Maller, J. L.
(1986)
J. Biol. Chem.
261,
350-356[Abstract/Free Full Text]
|
| 11.
|
Lewis, T. S.,
Shapiro, P. S.,
and Ahn, N. G.
(1998)
Adv. Cancer Res.
74,
49-139[Medline]
[Order article via Infotrieve]
|
| 12.
|
Meloche, S.,
Seuwen, K.,
Pages, G.,
and Pouyssegur, J.
(1992)
Mol. Endocrinol.
6,
845-854[Abstract/Free Full Text]
|
| 13.
|
York, R. D.,
Yao, H.,
Dillon, T.,
Ellig, C. L.,
Eckert, S. P.,
McCleskey, E. W.,
and Stork, P. J.
(1998)
Nature
392,
622-626[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Jin, Z. G.,
Melaragno, M. G,
Liao, D. F.,
Yan, C.,
Haendeler, J.,
Suh, Y. A.,
Lambeth, J. D.,
and Berk, B. C.
(2000)
Circ. Res.
87,
789-796[Abstract/Free Full Text]
|
| 15.
|
Aikawa, R.,
Komuro, I.,
Yamazaki, T.,
Zou, Y.,
Kudoh, S.,
Tanaka, M.,
Shiojima, I.,
Hiroi, Y.,
and Yazaki, Y.
(1997)
J. Clin. Invest.
100,
1813-1821[Medline]
[Order article via Infotrieve]
|
| 16.
|
David, J. R.
(1966)
Proc. Natl. Acad. Sci. U. S. A.
56,
72-77[Free Full Text]
|
| 17.
|
Bloom, B. R.,
and Bennett, B.
(1966)
Science
153,
80-82[Abstract/Free Full Text]
|
| 18.
|
Calandra, T.,
Bernhagen, J.,
Metz, C. N.,
Spiegel, L. A.,
Bacher, M.,
Donnelly, T.,
Cerami, A.,
and Bucala, R.
(1995)
Nature
377,
68-71[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Bacher, M.,
Metz, C. N.,
Calandra, T.,
Mayer, K.,
Chesney, J.,
Lohoff, M.,
Gemsa, D.,
Donnelly, T.,
and Bucala, R.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7849-7854[Abstract/Free Full Text]
|
| 20.
|
Kleemann, R.,
Hausser, A.,
Geiger, G.,
Mischke, R.,
Burger-Kentischer, A.,
Flieger, O.,
Johannes, F.,
Roger, T.,
Calandra, T.,
Kapurniotu, A.,
Grell, M.,
Finkelmeier, D.,
Brunner, H.,
and Bernhagen, J.
(2000)
Nature
408,
211-216[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Bernhagen, J.,
Calandra, T.,
Mitchell, R. A.,
Martin, S. B.,
Tracey, K. J.,
Voelter, W.,
Manogue, K. R.,
Cerami, A.,
and Bucala, R.
(1993)
Nature
365,
756-759[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Lin, S. G., Yu, X. Y.,
Chen, Y. X.,
Huang, X. R.,
Metz, C.,
Bucala, R.,
Lau, C. P.,
and Lan, H. Y.
(2000)
Circ. Res.
87,
1202-1208[Abstract/Free Full Text]
|
| 23.
|
Yu, C.,
Lau, C.,
Lai, K. W.,
Huang, X.,
Chen, W.,
and Lan, H. Y.
(2001)
Am. J. Cardiol.
88,
774-777[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Nishihira, J.,
Kuriyama, T.,
Sakai, M.,
Nishi, S.,
Ohki, S.,
and Hikichi, K.
(1995)
Biochim. Biophys. Acta
1247,
159-162[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Nishio, Y.,
Mianami, A.,
Kato, H.,
Kaneda, K.,
and Nishihira, J.
(1999)
Biochim. Biophys. Acta
1453,
74-82[Medline]
[Order article via Infotrieve]
|
| 26.
|
Booz, G. W.,
Dostal, D. E.,
Singer, H. A.,
and Baker, K. M.
(1994)
Am. J. Physiol.
267,
C1308-C1318[Abstract/Free Full Text]
|
| 27.
|
Hunt, R. A.,
Bhat, G. J.,
and Baker, K. M.
(1999)
Hypertension
34,
603-608[Abstract/Free Full Text]
|
| 28.
|
Fukuzawa, J.,
Booz, G. W.,
Hunt, R. A.,
Shimizu, N.,
Karoor, V.,
Baker, K. M.,
and Dostal, D. E.
(2000)
Hypertension
35,
1191-1196[Abstract/Free Full Text]
|
| 29.
|
Booz, G. W.,
Dostal, D. E.,
and Baker, K. M.
(1996)
Hypertension
28,
635-640[Abstract/Free Full Text]
|
| 30.
|
Bhat, G. J.,
Thekkumkara, T. J.,
Thomas, W. G.,
Conrad, K. M.,
and Baker, K. M.
(1994)
J. Biol. Chem.
269,
31443-31449[Abstract/Free Full Text]
|
| 31.
|
Schagger, H.,
and von Jagow, G.
(1987)
Anal. Biochem.
166,
368-379[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Schulte, T. W.,
Blagosklonny, M. V.,
Romanova, L.,
Mushinski, J. F.,
Monia, B. P.,
Johnston, J. F.,
Nguyen, R.,
Trepei, J.,
and Neckers, L. M.
(1996)
Mol. Cell. Biol.
16,
5839-5845[Abstract]
|
| 33.
|
Sadoshima, J.,
and Izumo, S.
(1997)
Annu. Rev. Physiol.
59,
551-571[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Dempsey, E. C.,
Newton, A. C.,
Mochly-Rosen, D.,
Fields, A. P.,
Reyland, M. E.,
Insel, P. A.,
and Messing, R. O.
(2000)
Am. J. Physiol.
279,
L429-L438
|
| 35.
|
Linke, M, J.,
Burton, F. M.,
Fiedeldey, D. T.,
and Rice, W. R.
(1997)
Am. J. Physiol.
272,
L171-L177[Abstract/Free Full Text]
|
| 36.
|
Koong, A. C.,
Denko, N. C.,
Hudson, K. M.,
Schindler, C.,
Swiersz, L.,
Koch, C.,
Evans, S.,
Ibrahim, H., Le, Q. T.,
Terris, D. J.,
and Giaccia, A. J.
(2000)
Cancer Res.
60,
883-887[Abstract/Free Full Text]
|
| 37.
|
Sugimoto, H.,
Suzuki, M.,
Nakagawa, A.,
Tanaka, I.,
and Nishihira, J.
(1996)
FEBS Lett.
389,
145-148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Sun, H.,
Bernhagen, J.,
Bucala, R.,
and Lolis, E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5191-5196[Abstract/Free Full Text]
|
| 39.
|
Suzuki, M.,
Sugimoto, H.,
Nakagawa, A.,
Tanaka, I.,
Nishihira, J.,
and Sakai, M.
(1996)
Nat. Struct. Biol.
3,
259-266[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Bendrat, K., Al-,
Abed, Y.,
Callaway, D. J. I.,
Peng, T.,
Calandra, T.,
Metz, C. N.,
and Bucala, R.
(1997)
Biochemistry
36,
15363-15370[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Mischke, R.,
Kleemann, R.,
Brunner, H.,
and Bernhagen, J.
(1998)
FEBS Lett.
427,
85-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Mitchel, R. A.,
Metz, C. M.,
Peng, T.,
and Bucala, R.
(1999)
J. Biol. Chem.
274,
18100-18106[Abstract/Free Full Text]
|
| 43.
|
Sano, M.,
Fukuda, K.,
Sato, T.,
Kawaguchi, H.,
Suematsu, M.,
Matsuda, S.,
Koyasu, S.,
Matsui, H.,
Yamauchi-Takihara, K.,
Harada, M.,
Saito, Y.,
and Ogawa, S.
(2001)
Circ. Res.
89,
661-669[Abstract/Free Full Text]
|
| 44.
|
Takahashi, M.,
Nishihira, J.,
Shimpo, M.,
Mizue, Y.,
Ikeda, U.,
and Shimada, K.
(2001)
Cardiovasc. Res.
52,
438-445[Abstract/Free Full Text]
|
| 45.
|
Irons, C. E.,
Sei, C. A.,
and Glembotski, C. C.
(1993)
Am. J. Physiol.
264,
H282-H285[Abstract/Free Full Text]
|
| 46.
|
Kaye, D.,
Pemental, D.,
Prasad, S.,
Maki, T.,
Berger, H. J.,
McNeil, P. L.,
Smith, T. W.,
and Kelly, R. A.
(1996)
J. Clin. Invest.
97,
281-291[Medline]
[Order article via Infotrieve]
|
| 47.
|
Barrie, A. P.,
Clohessy, A. M.,
Buensuceso, C. S.,
Rogers, M. V.,
and Allen, J. M.
(1997)
J. Biol. Chem.
272,
19666-19671[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Zernecke, J. Bernhagen, and C. Weber
Macrophage Migration Inhibitory Factor in Cardiovascular Disease
Circulation,
March 25, 2008;
117(12):
1594 - 1602.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ikeda, A. Murakami, Y. Fujimura, H. Tachibana, K. Yamada, D. Masuda, K.-i. Hirano, S. Yamashita, and H. Ohigashi
Aggregated Ursolic Acid, a Natural Triterpenoid, Induces IL-1beta Release from Murine Peritoneal Macrophages: Role of CD36
J. Immunol.,
April 15, 2007;
178(8):
4854 - 4864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Lehmann, S. Schroeder, W. Hartmann, O. Dewald, M. Book, S. U. Weber, J.-C. Schewe, and F. Stuber
A single nucleotide polymorphism of macrophage migration inhibitory factor is related to inflammatory response in coronary bypass surgery using cardiopulmonary bypass.
Eur. J. Cardiothorac. Surg.,
July 1, 2006;
30(1):
59 - 63.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Willis, D. L. Carlson, J. M. DiMaio, M. D. White, D. J. White, G. A. Adams IV, J. W. Horton, and B. P. Giroir
Macrophage migration inhibitory factor mediates late cardiac dysfunction after burn injury
Am J Physiol Heart Circ Physiol,
February 1, 2005;
288(2):
H795 - H804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. B. Garner, M. S. Willis, D. L. Carlson, J. M. DiMaio, M. D. White, D. J. White, G. A. Adams IV, J. W. Horton, and B. P. Giroir
Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor
Am J Physiol Heart Circ Physiol,
December 1, 2003;
285(6):
H2500 - H2509.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ramer, U. Weinzierl, B. Schwind, K. Brune, and B. Hinz
Ceramide Is Involved in R(+)-Methanandamide-Induced Cyclooxygenase-2 Expression in Human Neuroglioma Cells
Mol. Pharmacol.,
November 1, 2003;
64(5):
1189 - 1198.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|